TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07392372: A Phase I First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of the Broadly Neutralizing Antibody BNT351 in Adults Living Without and With HIV

Sponsor: BioNTech SE · Phase: PHASE1 · Area: INFECTIOUS_VACCINE · Target Enrollment: 67 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$2,978,808

Rescue Site Savings

+$1,959,216

Unlock Full NCT07392372 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07392372 Rescue Dossier →